Marcus Dahllöf - Introductory Remarks
Swiss RE has implemented their main Investment Management Platform > 10y ago, still using additional applications for similar services and added multiple additional ad on software applications. Besides comparing the known players on the market (e. g. Aladdin, Murex, Charles River, Simcorp, Bloomberg AIM) we would also like to know if there are new players in the market, maybe using better technology.
A $17B/year global leader in automotive technologies, Faurecia is anticipating all the challenges of a changing industry. With the help of strategic partnerships with companies, start-ups and academia within an open innovation ecosystem, Faurecia technologies address two key aspects of mobility: the Cockpit of the Future for a safer, more comfortable, and more intuitive experience in the cockpit of the future, and Sustainable Mobility for cleaner and more environmentally-friendly transportation around the world. Owns more than 300 assembly lines in the US.
Catherine Havasi, CEO, Luminoso
This year’s theme will be built around ensuring the durability of the energy transition in the face of future unknowns.
MIT Startup Exchange presents its September Startup Workshop, centered around real-world IoT and edge computing. Many companies are grappling with how to use IoT and data/AI in their organization to monitor, predict, improve, and transform what they do. Meanwhile, many MIT startups are developing and providing innovative technology solutions to answer these very questions for industry. This workshop will present perspectives from industry leaders, academics, and corporate investors, while also showcasing select MIT startups in the field.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.